Jingyao Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jingyao Liu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Hui Zhu
Department of Neurology, The First Hospital, Jilin University, Changchun, China
12 shared publicationsTeng Zhao
5 shared publicationsHongchao Liu
Department of Neurology, The First Hospital, Jilin University, Changchun, China
2 shared publicationsRensheng Zhang
Department of Neurology, First Hospital, Jilin University, Changchun, Jilin 130031, P.R. China
2 shared publicationsWanting Hou
Medical College of YanbianUniversity, Yanbian University, Yanji, China
2 shared publicationsXuemin Feng
Department of Neurology, The First Hospital, Jilin University, Jinlin, China
2 shared publications
Latest Publications
- Open Access
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 24 (3) , 340-347
Neutrophil Extracellular Traps in Central Nervous System Diseases
Neutrophil Extracellular Traps (NETs) are complexes containing DNA fibrils and antimicrobial peptides that are released by neutrophils in response to pathogen stimulation. At the time of their discovery, the neutrophil extracellular trap contained active substances such as Neutrophil Elastase (NE) and myeloperoxidase (MPO). Although NETs were initially thought to be a means for the innate immune system to fight microbial invasion, now they have been observed to have a broader impact throughout the body. In recent studies, NETs have been linked to several neurological disorders and have been found to have varying roles in a number of diseases. In addition to their role in thrombosis, NETs have been identified in various autoimmune diseases. NETs play a significant role in the body when they are produced at the correct time and place; however, when the generation and removal of NETs are out of equilibrium, there can be important implications for human health. Here, the impact of NETs is reviewed in various neurological disorders and their potential clinical applications.
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 24 (3) , 340-347
Open AccessNeutrophil Extracellular Traps in Central Nervous System Diseases
Neutrophil Extracellular Traps (NETs) are complexes containing DNA fibrils and antimicrobial peptides that are released by neutrophils in response to pathogen stimulation. At the time of their discovery, the neutrophil extracellular trap contained active substances such as Neutrophil Elastase (NE) and myeloperoxidase (MPO). Although NETs were initially thought to be a means for the innate immune system to fight microbial invasion, now they have been observed to have a broader impact throughout the body. In recent studies, NETs have been linked to several neurological disorders and have been found to have varying roles in a number of diseases. In addition to their role in thrombosis, NETs have been identified in various autoimmune diseases. NETs play a significant role in the body when they are produced at the correct time and place; however, when the generation and removal of NETs are out of equilibrium, there can be important implications for human health. Here, the impact of NETs is reviewed in various neurological disorders and their potential clinical applications.
- Open Access
- 18 March 2025
- Published by SAGE Publications in Annals of Neurosciences
- Vol. 33 (1) , 115-122
Hereditary Haemorrhagic Cerebrovascular Disease: Implications for Clinical Management
Background: At present, treatment of hereditary haemorrhagic cerebrovascular disease remains in the symptomatic stage. It is more important to provide strategies for developing rational treatment methods, expanding our understanding with regard to the pathophysiology in the context of familial diseases. Summary: In this article, the combined data from the literature on diseases, including familial cerebral cavernous haemangiomas, hereditary cerebral haemorrhage with amyloidosis, familial intracranial aneurysms, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, were reviewed to manage the haemorrhagic diseases discussed through genetic counselling and early prevention and treatment of these patients and their families, the genetics, pathogenesis, clinical manifestations and treatment. Key Messages: It is important to understand and treat hereditary haemorrhagic cerebrovascular disease through genetic treatment options.
- 18 March 2025
- Published by SAGE Publications in Annals of Neurosciences
- Vol. 33 (1) , 115-122
Open AccessHereditary Haemorrhagic Cerebrovascular Disease: Implications for Clinical Management
Background: At present, treatment of hereditary haemorrhagic cerebrovascular disease remains in the symptomatic stage. It is more important to provide strategies for developing rational treatment methods, expanding our understanding with regard to the pathophysiology in the context of familial diseases. Summary: In this article, the combined data from the literature on diseases, including familial cerebral cavernous haemangiomas, hereditary cerebral haemorrhage with amyloidosis, familial intracranial aneurysms, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, were reviewed to manage the haemorrhagic diseases discussed through genetic counselling and early prevention and treatment of these patients and their families, the genetics, pathogenesis, clinical manifestations and treatment. Key Messages: It is important to understand and treat hereditary haemorrhagic cerebrovascular disease through genetic treatment options.
- 1 January 2023
- Vol. 44 (6) , 341-344
A 106-year-old patient with unexpected COVID-19 pneumonia: A case report
The fast spread of COVID-19, which was caused by SARS-CoV-2 infection, has posed a major challenge to public health systems around the world. Morbidity and mortality are higher in the elderly than in the young, due to a loss in immune function and more comorbidities. In this case, we describe a 106-year-old female patient, the oldest COVID-19 patient since 2019, who had not previously received the SARS-CoV-2 vaccine. Her clinical symptoms included cough and sputum production. Images of her chest CT showed double lung pneumonia, and laboratory tests revealed elevated serum KL-6 levels. She was mostly on oral medication during her hospitalization and recovered well. With the case, we discuss the risk factors and biomarkers correlated to COVID-19 severity. Following the COVID outbreak, it's vital to explore the possible risk factors that can help with disease risk stratification, identifying high-risk individuals, developing precise treatment regimens, and lowering mortality rates.
- 1 January 2023
- Vol. 44 (6) , 341-344
A 106-year-old patient with unexpected COVID-19 pneumonia: A case report
The fast spread of COVID-19, which was caused by SARS-CoV-2 infection, has posed a major challenge to public health systems around the world. Morbidity and mortality are higher in the elderly than in the young, due to a loss in immune function and more comorbidities. In this case, we describe a 106-year-old female patient, the oldest COVID-19 patient since 2019, who had not previously received the SARS-CoV-2 vaccine. Her clinical symptoms included cough and sputum production. Images of her chest CT showed double lung pneumonia, and laboratory tests revealed elevated serum KL-6 levels. She was mostly on oral medication during her hospitalization and recovered well. With the case, we discuss the risk factors and biomarkers correlated to COVID-19 severity. Following the COVID outbreak, it's vital to explore the possible risk factors that can help with disease risk stratification, identifying high-risk individuals, developing precise treatment regimens, and lowering mortality rates.
- Open Access
- 9 December 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (49) , e31851
Thrombotic thrombocytopenic purpura with neurological impairment: A Review
The last 2 decades have witnessed considerable advances in our understanding of thrombotic thrombocytopenic purpura (TTP). However, there is still some ambiguity regarding the precise nature of this disease, especially with respect to nervous system involvement and the correct nomenclature. This article seeks to summarize the clinical manifestations of TTP and the associated diseases. We describe TTP complicated with cerebrovascular disease, spinal cord injury, posterior reversible encephalopathy syndrome (PRES), anxious-depressive symptoms, and cognitive decline. TTP with spinal cord injury is rarely reported. For better clarity, we discuss the case of a 57-year-old woman who was diagnosed with neuromyelitis optica spectrum disease (NMOSD) with atypical TTP. The concurrent occurrence of NMOSD and TTP in this patient is consistent with the characteristics of acquired autoimmunity. We highlight the importance of early recognition of TTP in patients with atypical presentation who may not have the expected clinical or laboratory findings. This is particularly important in TTP patients with other concomitant autoimmune diseases or age-related comorbid conditions.
- 9 December 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (49) , e31851
Open AccessThrombotic thrombocytopenic purpura with neurological impairment: A Review
The last 2 decades have witnessed considerable advances in our understanding of thrombotic thrombocytopenic purpura (TTP). However, there is still some ambiguity regarding the precise nature of this disease, especially with respect to nervous system involvement and the correct nomenclature. This article seeks to summarize the clinical manifestations of TTP and the associated diseases. We describe TTP complicated with cerebrovascular disease, spinal cord injury, posterior reversible encephalopathy syndrome (PRES), anxious-depressive symptoms, and cognitive decline. TTP with spinal cord injury is rarely reported. For better clarity, we discuss the case of a 57-year-old woman who was diagnosed with neuromyelitis optica spectrum disease (NMOSD) with atypical TTP. The concurrent occurrence of NMOSD and TTP in this patient is consistent with the characteristics of acquired autoimmunity. We highlight the importance of early recognition of TTP in patients with atypical presentation who may not have the expected clinical or laboratory findings. This is particularly important in TTP patients with other concomitant autoimmune diseases or age-related comorbid conditions.
- 1 January 2022
- Vol. 43 (2) , 107-112
Genetic characteristics of Chinese patients with hemorrhagic cerebrovascular disease
BACKGROUND: We investigate the clinical and genetic characteristics of hemorrhagic cerebrovascular disease in order to provide a new theoretical basis for the prevention and treatment of hereditary cerebrovascular disease. METHOD: Three hereditary cerebral hemorrhage cases were analyzed retrospectively. The patients' families were surveyed, the clinical characteristics summarized, and gene polymorphisms investigated. RESULTS: Among the three cases, two patients had familial cerebral cavernous hemangiomas, and genetic testing revealed a heterozygous mutation in the CCM1 gene, with a deletion of base (T) in exon 15 (c.1542delT). The last patient had hereditary cerebral hemorrhage with amyloidosis, Finnish type, and the proband, his mother, and his daughter were found to have a heterozygous G duplicate mutation at position 100 in exon 1 of the GSN gene (c.100dupG). CONCLUSIONS: Future screening for genetic mutations associated with a highrisk of hereditary cerebral hemorrhage can help identify individuals at risk for this condition and thereby reduce the occurrence and progression of the disease. Such screening will further enhance the precision in preventing and treating cerebrovascular diseases.
- 1 January 2022
- Vol. 43 (2) , 107-112
Genetic characteristics of Chinese patients with hemorrhagic cerebrovascular disease
BACKGROUND: We investigate the clinical and genetic characteristics of hemorrhagic cerebrovascular disease in order to provide a new theoretical basis for the prevention and treatment of hereditary cerebrovascular disease. METHOD: Three hereditary cerebral hemorrhage cases were analyzed retrospectively. The patients' families were surveyed, the clinical characteristics summarized, and gene polymorphisms investigated. RESULTS: Among the three cases, two patients had familial cerebral cavernous hemangiomas, and genetic testing revealed a heterozygous mutation in the CCM1 gene, with a deletion of base (T) in exon 15 (c.1542delT). The last patient had hereditary cerebral hemorrhage with amyloidosis, Finnish type, and the proband, his mother, and his daughter were found to have a heterozygous G duplicate mutation at position 100 in exon 1 of the GSN gene (c.100dupG). CONCLUSIONS: Future screening for genetic mutations associated with a highrisk of hereditary cerebral hemorrhage can help identify individuals at risk for this condition and thereby reduce the occurrence and progression of the disease. Such screening will further enhance the precision in preventing and treating cerebrovascular diseases.
- 24 December 2021
- Published by Wiley in Annals of Neurology
- Vol. 91 (3) , 380-388
Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Objective: This study was undertaken to identify the risk of bleeding events and potential risk factors within 90 days in patients who carried CYP2C19 loss‐of‐function alleles and received dual antiplatelet therapy after minor stroke or transient ischemic attack.Methods: A total of 6,412 patients were enrolled from the CHANCE‐2 (Clopidogrel with Aspirin in High‐Risk Patients with Acute Non‐disabling Cerebrovascular Events II) trial. The main outcome was any bleeding within 90 days defined by the criteria from GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries).Results: A total of 250 (3.9%) bleeding events were reported, which occurred mainly within the 21 days of dual antiplatelet therapy (200 cases, 3.1%). Minor bleeding of the skin bruises, epistaxis, and gum bleeding were most frequent. Multivariate analysis showed that treatment with ticagrelor‐aspirin compared with clopidogrel‐aspirin was associated with increased bleeding (hazard ratio [HR] = 2.21, 95% confidence interval [CI] = 1.68–2.89, p < 0.001). Current smoking was associated with a lower risk of bleeding (HR = 0.70, 95% CI = 0.52–0.95, p = 0.02). Additionally, ticagrelor‐aspirin compared with clopidogrel‐aspirin was associated with higher risk of bleeding in patients aged p for interaction = 0.04 and 0.03, respectively).Interpretation: Bleeding events mostly occurred within the 21‐day dual antiplatelet therapy stage and were generally mild. The risk of bleeding was greater in nonsmoking patients, and was associated with treatment with ticagrelor‐aspirin compared with clopidogrel‐aspirin, particularly in patients aged <65 years and nondiabetic patients. ANN NEUROL 2022;91:380–388
- 24 December 2021
- Published by Wiley in Annals of Neurology
- Vol. 91 (3) , 380-388
Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Objective: This study was undertaken to identify the risk of bleeding events and potential risk factors within 90 days in patients who carried CYP2C19 loss‐of‐function alleles and received dual antiplatelet therapy after minor stroke or transient ischemic attack.Methods: A total of 6,412 patients were enrolled from the CHANCE‐2 (Clopidogrel with Aspirin in High‐Risk Patients with Acute Non‐disabling Cerebrovascular Events II) trial. The main outcome was any bleeding within 90 days defined by the criteria from GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries).Results: A total of 250 (3.9%) bleeding events were reported, which occurred mainly within the 21 days of dual antiplatelet therapy (200 cases, 3.1%). Minor bleeding of the skin bruises, epistaxis, and gum bleeding were most frequent. Multivariate analysis showed that treatment with ticagrelor‐aspirin compared with clopidogrel‐aspirin was associated with increased bleeding (hazard ratio [HR] = 2.21, 95% confidence interval [CI] = 1.68–2.89, p < 0.001). Current smoking was associated with a lower risk of bleeding (HR = 0.70, 95% CI = 0.52–0.95, p = 0.02). Additionally, ticagrelor‐aspirin compared with clopidogrel‐aspirin was associated with higher risk of bleeding in patients aged p for interaction = 0.04 and 0.03, respectively).Interpretation: Bleeding events mostly occurred within the 21‐day dual antiplatelet therapy stage and were generally mild. The risk of bleeding was greater in nonsmoking patients, and was associated with treatment with ticagrelor‐aspirin compared with clopidogrel‐aspirin, particularly in patients aged <65 years and nondiabetic patients. ANN NEUROL 2022;91:380–388
- Open Access
- 17 May 2021
- Published by Springer Nature in Research Square
Genetic Characteristics of Chinese Patients With Hemorrhagic Cerebrovascular Disease
BackgroundWe investigate the clinical and genetic characteristics of hemorrhagic cerebrovascular disease in order to provide a new theoretical basis for the prevention and treatment of hereditary cerebrovascular disease. Case presentationThree hereditary cerebral hemorrhage cases were analyzed retrospectively. The patients’ families were surveyed, the clinical characteristics summarized, and gene polymorphisms investigated. Among the three cases, two patients had familial cerebral cavernous hemangiomas, and genetic testing revealed a heterozygous mutation in the CCM1 gene, with a deletion of base (T) in exon 15 (c.1542delT). This mutation was also found in three family members of one proband who all had a history of cerebrovascular disease, while genetic testing was normal for the proband’s unaffected family member. The last patient had hereditary cerebral hemorrhage with amyloidosis, Finnish type, and the proband, his mother, and his daughter were found to have a heterozygous G duplicate mutation at position 100 in exon 1 of the GSN gene (c.100dupG). ConclusionsFuture screening for genetic mutations associated with a high-risk of hereditary cerebral hemorrhage can help identify individuals at risk for this condition and thereby reduce the occurrence and progression of the disease. Such screening will further enhance the precision in preventing and treating cerebrovascular diseases.
- 17 May 2021
- Published by Springer Nature in Research Square
Open AccessGenetic Characteristics of Chinese Patients With Hemorrhagic Cerebrovascular Disease
BackgroundWe investigate the clinical and genetic characteristics of hemorrhagic cerebrovascular disease in order to provide a new theoretical basis for the prevention and treatment of hereditary cerebrovascular disease. Case presentationThree hereditary cerebral hemorrhage cases were analyzed retrospectively. The patients’ families were surveyed, the clinical characteristics summarized, and gene polymorphisms investigated. Among the three cases, two patients had familial cerebral cavernous hemangiomas, and genetic testing revealed a heterozygous mutation in the CCM1 gene, with a deletion of base (T) in exon 15 (c.1542delT). This mutation was also found in three family members of one proband who all had a history of cerebrovascular disease, while genetic testing was normal for the proband’s unaffected family member. The last patient had hereditary cerebral hemorrhage with amyloidosis, Finnish type, and the proband, his mother, and his daughter were found to have a heterozygous G duplicate mutation at position 100 in exon 1 of the GSN gene (c.100dupG). ConclusionsFuture screening for genetic mutations associated with a high-risk of hereditary cerebral hemorrhage can help identify individuals at risk for this condition and thereby reduce the occurrence and progression of the disease. Such screening will further enhance the precision in preventing and treating cerebrovascular diseases.
- Open Access
- 26 March 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (12) , e25160
Pathogenic variants of PROC gene caused type II activity deficiency in a Chinese family
Rationale: Hereditary Protein C (PC) deficiency is a rare genetic disorder caused by PROC gene mutation. In this article, we report a case of PC deficiency in a Chinese family due to a novel PROC gene mutation. Study Subject: The proband presented with recurrent cerebral infarction over the course of the previous 3 years. He was admitted to the hospital due to signs of mental retardation. Diagnoses: Physical examination, laboratory tests, and magnetic resonance imaging demonstrated that the proband had a manifestation of PC deficiency that included acute cerebral infarction. DNA sequencing analysis revealed a missense variant, c.1015G > A (p.V339 M from valine to methionine) in exon 9 of the PROC gene. In addition, Sanger sequencing confirmed that the proband's son was heterozygous for the same variant. Therefore, the PROC gene mutation was transmitted in an autosomal dominant inheritance manner. Interventions: The patient was treated with a daily dosage of Warfarin (3.5 mg) and was scheduled to undergo regular blood coagulation tests. Outcomes: At the 3-month follow-up appointment, the patient showed improvements in his overall health condition. Lessons: We identified a novel missense mutation in the PROC gene in a Chinese family which caused a decrease in the PC antigen level and recurrent cerebral infarction.
- 26 March 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (12) , e25160
Open AccessPathogenic variants of PROC gene caused type II activity deficiency in a Chinese family
Rationale: Hereditary Protein C (PC) deficiency is a rare genetic disorder caused by PROC gene mutation. In this article, we report a case of PC deficiency in a Chinese family due to a novel PROC gene mutation. Study Subject: The proband presented with recurrent cerebral infarction over the course of the previous 3 years. He was admitted to the hospital due to signs of mental retardation. Diagnoses: Physical examination, laboratory tests, and magnetic resonance imaging demonstrated that the proband had a manifestation of PC deficiency that included acute cerebral infarction. DNA sequencing analysis revealed a missense variant, c.1015G > A (p.V339 M from valine to methionine) in exon 9 of the PROC gene. In addition, Sanger sequencing confirmed that the proband's son was heterozygous for the same variant. Therefore, the PROC gene mutation was transmitted in an autosomal dominant inheritance manner. Interventions: The patient was treated with a daily dosage of Warfarin (3.5 mg) and was scheduled to undergo regular blood coagulation tests. Outcomes: At the 3-month follow-up appointment, the patient showed improvements in his overall health condition. Lessons: We identified a novel missense mutation in the PROC gene in a Chinese family which caused a decrease in the PC antigen level and recurrent cerebral infarction.
- Open Access
- 26 September 2019
- Published by Wiley in Brain and Behavior
- Vol. 9 (10) , e01416
A novel ABCD1 gene mutation causes adrenomyeloneuropathy in a Chinese family
Background: Adrenomyeloneuropathy (AMN) is a rare genetic disease. In this study, a case of AMN was uncovered in a Chinese family.Methods: Clinical manifestations were collected and observed through medical records, physical examination, laboratory tests, and magnetic resonance imaging (MRI). Generation sequencing of the ABCD1 gene was performed, and the pedigree of the family was analyzed.Results: The proband suffered from adrenocortical insufficiency at 8 years old and presented with a slowly progressive gait disorder at 21 years old. Physical examination, laboratory tests, and MRI showed that he had adult‐onset AMN manifestations, including spasticity and hyperactive tendon reflexes with Hoffman and Babinski signs in the limbs, difficulty in performing the heel‐to‐shin test, hyperpigmentation, increased levels of adrenocorticotropic hormone and very long‐chain fatty acids, decreased levels of corticosteroid and serum gesterol, and salient atrophy of the cervical and thoracic spinal cord. DNA analysis revealed a missense variant, c.290A>C (p.His97Pro) in exon 1 of the ABCD1 gene, in the proband. Sanger sequencing confirmed that the proband's mother was heterozygous for the same variant. The ABCD1 gene mutation transmitted in an X‐linked inheritance manner.Conclusion: A novel missense mutation in the ABCD1 gene was identified in a Chinese family, which caused an unusual manifestation of adult‐onset AMN. This discovery is beneficial for the genetic counseling of patients with X‐linked adrenoleukodystrophy.
- 26 September 2019
- Published by Wiley in Brain and Behavior
- Vol. 9 (10) , e01416
Open AccessA novel ABCD1 gene mutation causes adrenomyeloneuropathy in a Chinese family
Background: Adrenomyeloneuropathy (AMN) is a rare genetic disease. In this study, a case of AMN was uncovered in a Chinese family.Methods: Clinical manifestations were collected and observed through medical records, physical examination, laboratory tests, and magnetic resonance imaging (MRI). Generation sequencing of the ABCD1 gene was performed, and the pedigree of the family was analyzed.Results: The proband suffered from adrenocortical insufficiency at 8 years old and presented with a slowly progressive gait disorder at 21 years old. Physical examination, laboratory tests, and MRI showed that he had adult‐onset AMN manifestations, including spasticity and hyperactive tendon reflexes with Hoffman and Babinski signs in the limbs, difficulty in performing the heel‐to‐shin test, hyperpigmentation, increased levels of adrenocorticotropic hormone and very long‐chain fatty acids, decreased levels of corticosteroid and serum gesterol, and salient atrophy of the cervical and thoracic spinal cord. DNA analysis revealed a missense variant, c.290A>C (p.His97Pro) in exon 1 of the ABCD1 gene, in the proband. Sanger sequencing confirmed that the proband's mother was heterozygous for the same variant. The ABCD1 gene mutation transmitted in an X‐linked inheritance manner.Conclusion: A novel missense mutation in the ABCD1 gene was identified in a Chinese family, which caused an unusual manifestation of adult‐onset AMN. This discovery is beneficial for the genetic counseling of patients with X‐linked adrenoleukodystrophy.
- 1 January 2019
- Vol. 40 (3) , 113-118
Carotid Artery Stenosis after Radiation Therapy in a Patient with Lung Cancer: A Case Report and Literature Review
We reported a case of carotid artery stenosis with stroke symptoms detected in a patient with lung cancer after radiotherapy. The patient was a 58-year-old male with a complaint of "a single episode of temporary amaurosis in the right eye for 10 minutes". The clinical diagnosis at admission, after consideration of the patient's age, medical history, and auxiliary examination results, was as follows: lung cancer; right common carotid artery stenosis; left common carotid artery stenosis; left vertebral artery stenosis; and right subclavian artery occlusion with right subclavian steal syndrome (Grade 3). Carotid angioplasty and stenting (CAS) were subsequently performed. During the 6-month follow-up, we observed no episode of temporary vision loss or other signs of stroke. Clinicians should pay great attention to delayed radiation-induced carotid stenosis. It is recommended that patients with a history of radiotherapy should undergo regular color Doppler ultrasound examination of the cervical region to diagnose, prevent, and treat RICS in an expedient fashion. This approach should improve survival rate and quality of life.
- 1 January 2019
- Vol. 40 (3) , 113-118
Carotid Artery Stenosis after Radiation Therapy in a Patient with Lung Cancer: A Case Report and Literature Review
We reported a case of carotid artery stenosis with stroke symptoms detected in a patient with lung cancer after radiotherapy. The patient was a 58-year-old male with a complaint of "a single episode of temporary amaurosis in the right eye for 10 minutes". The clinical diagnosis at admission, after consideration of the patient's age, medical history, and auxiliary examination results, was as follows: lung cancer; right common carotid artery stenosis; left common carotid artery stenosis; left vertebral artery stenosis; and right subclavian artery occlusion with right subclavian steal syndrome (Grade 3). Carotid angioplasty and stenting (CAS) were subsequently performed. During the 6-month follow-up, we observed no episode of temporary vision loss or other signs of stroke. Clinicians should pay great attention to delayed radiation-induced carotid stenosis. It is recommended that patients with a history of radiotherapy should undergo regular color Doppler ultrasound examination of the cervical region to diagnose, prevent, and treat RICS in an expedient fashion. This approach should improve survival rate and quality of life.